CTRI/2026/04/107954尚未招募3 期
Efficacy and Safety of Single-Inhaler Triple Therapy (SITT) of Fluticasone Furoate, Umeclidinium and Vilanterol inhalation– (50 mcg/31.25 mcg/12.5 mcg) Metered dose inhaler (MDI) versus SITT of TRELEGY ELLIPTA, Dry powder inhaler (DPI) [Fluticasone Furoate, Umeclidinium and Vilanterol Powder for oral inhalation – (100 mcg/62.5 mcg/25 mcg)] in Chronic Obstructive Pulmonary Disease (COPD) participants: A Multi-center, Randomized, Open-label, Comparative, Parallel Group Study.
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 230
- 试验地点
- 18
研究概览
简要总结
Chronic obstructive pulmonary disease (COPD) is a progressive chronic disease which is subject to acute exacerbations. COPD is a multicomponent integration of chronic and progressive illnesses, characterized by airway obstruction, inflammation, hyperinflation and acute-on-chronic exacerbations. Airway obstruction in COPD is an important cause of exertional breathlessness. It slowly progresses to marked disability and respiratory failure to limit the daily activities of an individual, finally confining him to bed.
COPD is a multicomponent disease that also affects the systems and organs outside the lungs. These systemic effects of COPD include weight loss, muscle dysfunction and cardiovascular disease. The subjects with COPD have a lower physical activity level even earlier in the disease process.
The Purpose of the study is to Efficacy and Safety of Single-Inhaler Triple Therapy (SITT) of Fluticasone Furoate, Umeclidinium and Vilanterol inhalation– (50 mcg/31.25 mcg/12.5 mcg) Metered dose inhaler (MDI) versus SITT of TRELEGY ELLIPTA, Dry powder inhaler (DPI) [Fluticasone Furoate, Umeclidinium and Vilanterol Powder for oral inhalation – (100 mcg/62.5 mcg/25 mcg)] in Chronic Obstructive Pulmonary Disease (COPD) participants
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- None
入排标准
- 年龄范围
- 40.00 Year(s) 至 99.00 Year(s)（—）
- 性别
- All
入选标准
- •Male or female participants, aged grater than or equal to 40 years at screening.
- •Participants with a diagnosis of COPD (as defined by the GOLD COPD report 2025).
- •Post-bronchodilator FEV1 grater than or equal to 30% and less than 80% of the predicted normal value and post-bronchodilator FEV1/FVC (forced vital capacity) ratio less than 0.70
- •A modified Medical Research Council dyspnea scale (mMRC) grade grater than or equal to
- •COPD Assessment Test (CAT) score greater than or equal to 10 even after receiving at least two inhaled maintenance therapies (LABA Plus LAMA or LABA Plus ICS) for at least 4-6 weeks at the time of screening.
- •History of exacerbations (greater than or equal to 2 moderate or greater than or equal to 1 severe exacerbation) of COPD within 12 months before screening.
- •Subjects on inhaled corticosteroid (ICS) with or without a long-acting beta2 agonist (LABA) (as a free or fixed combination), or ICS with a long-acting muscarinic antagonist (LAMA), or LABA with LAMA (as a free or fixed combination), or LAMA monotherapy as maintenance treatment for at least 1 month before screening.
- •Willingness to give their written informed consent to participate in the study and willingness to comply with study requirements and procedures.
- •Female subjects with negative pregnancy tests, and agreed to use adequate forms of non-hormonal contraception during the study (i.e. women of childbearing potential used a highly effective method of birth control, such as condom and spermicide, diaphragm or cervical cap and spermicide, condom and diaphragm or cervical cap, non-hormonal IUD), or females who were of non-child bearing potential i.e. who were surgically sterile (history of hysterectomy or bilateral tubal ligation or bilateral oophorectomy; partial hysterectomy is not sufficient or vasectomized partner) or postmenopausal (12 months of spontaneous amenorrhea), or who agreed to remain abstinent.
- •Ability to use the test and reference products independently and correctly as instructed by the investigator.
排除标准
- •Participant unable to perform study procedures or not willing to give informed consent.
- •Participants already receiving triple drug treatment with LABA Plus LAMA Plus ICS (either in the form of SITT or MITT).
- •Participants with co-existing comorbidities such as tuberculosis, alpha-1 antitrypsin deficiency, cystic fibrosis, active bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, pulmonary edema, or interstitial lung disease.
- •Evidence or history of other clinically significant cardiovascular disease or abnormality (such as, but not limited to, congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infraction, arrhythmia, long QT syndrome, atrial fibrillation), renal, neurological, endocrine, immunological, psychiatric, hepatic, or hematological disease or abnormality which, in the opinion of the investigator, will clinically significant and have put the patient at risk through study participation, or would have affected the study analyses if the disease exacerbates during the study.
- •Significant abnormality that suggests chest disease other than COPD, on chest X-ray or computed tomography (CT) scan taken within six months before screening.
- •If there was no chest X-ray/CT scan taken within six months prior to screening, a chest X-ray will be performed during screening to rule out any other significant abnormality.
- •History of paradoxical bronchospasm, narrow-angle glaucoma, prostatic hyperplasia, bladder neck obstruction, severe renal impairment or urinary retention, or any other condition, which, in the opinion of the investigator, would have contraindicated the use of an anticholinergic or long-acting beta agonist agent.
- •Hospitalization for COPD exacerbation or pneumonia within three months prior to screening.
- •Use of oral/parenteral corticosteroids or antibiotics for COPD exacerbation within six weeks prior to screening.
- •A clinically significant abnormal electrocardiogram (ECG) at screening.
- •Lung volume reduction surgery within 12 months prior to the initiation of the study.
- •Requirement of long-term (greater than 12 hours daily) oxygen therapy.
- •Unable to stop the following medications at the defined times prior to screening spirometry: a.
- •Ipratropium or ipratropium/salbutamol combination product: 8 hours, Inhaled short-acting beta-agonists 6 hours, Oral beta 2-agonists 48 hours, Long acting beta agonists (salmeterol and formoterol) or ICS/LABA combination products: 48 hours, Xanthines: 48 hours, Cromolyn and nedocromil inhalers 24 hours b.
- •Zafirlukast, montelukast, zileuton: 48 hours Long-acting anticholinergics (Tiotropium etc.): 48 hours c.
- •Oral or parenteral corticosteroids: 6 weeks d.
- •Any other investigational medication 30 days or 5 half-lives of the investigational drug (whichever is longer), e.
- •Depot corticosteroids: 3 months, f.
- •Inhaled corticosteroids (ICS): Washout not required
- •Currently enrolled in another interventional clinical study or have used any IPs, study drug, or device within 30 days or 5 times the half-life, whichever is longer, preceding informed consent or scheduled to participate in another clinical study involving an IP.
- •Participants who are currently taking alcohol products.
研究者
Pramod Kadam
Lupin Limited
研究点 (18)
Loading locations...
相似试验
进行中（未招募）
3 期
A phase III trial to evaluate the Efficacy and Safety of test and reference product in moderate-severe COPD patient.CTRI/2025/08/092238Lupin Ltd.,230
招募中
1 期
Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell TherapyNCT07355868Regend Therapeutics12
尚未招募
2 期
Molecular efficacy evaluation of Agastya haritaki rasayana on chronic obstructive pulmonary disorder (COPD)CTRI/2026/03/105780Rajiv Gnadhi University of Health Sciences60
进行中（未招募）
不适用
AI-Powered Sound Analysis for COPD ScreeningNCT07457073Sir Run Run Shaw Hospital3,000
尚未招募
3 期
Role of Marichadi gutika and sitopaladi vati in management of Shwasa with special reference to Chronic obstructive pulmonary disease (COPD)CTRI/2024/04/066421Principal Parul Institute of Ayurved50